Alnylam's split into three units highlights its role as the area's most promising pre-commercial biotech

The Cambridge biotech that began the year with a bang with a big investment, Alnylam Pharmaceuticals, is ending it with a strategic plan announced today that cements its place perhaps the most promising pre-commercial biotech in a state full of dozens of promising biotechs...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.